Blueprint Medicines names Christoph Lengauer chief scientific officer

Friday, February 10, 2012 11:44 AM

Blueprint Medicines, a Cambridge, Mass.-based developer of personalized cancer therapies, has appointed Christoph Lengauer, Ph.D., chief scientific officer.

Lengauer most recently was vice president and global head of oncology drug discovery and preclinical development at Sanofi. Previously, he was executive director and senior unit head, oncology discovery at the Novartis Institutes for Biomedical Research, and an associate professor of oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University.

Lengauer has a proven track record in cancer drug discovery, including contributing to 17 development candidates, 11 drugs/programs that reached first-in-human clinical trials and two registered drugs. He is lead or senior author of several scientific articles published in journals such as Cell, Nature and Science.

"Christoph has been at the forefront of the development of several novel and effective cancer drugs that have had a significant impact on patients' lives and brings a powerful understanding of cancer drug development to Blueprint," said Nicholas Lydon, Ph.D., scientific co-founder of Blueprint Medicines. "He is uniquely suited to lead our cancer therapeutics development strategy, and we believe his appointment is a true validation of the potential of Blueprint Medicines' platform and our ability to leverage emerging molecular insights to develop genomically-driven, highly selective therapies."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 2

Roche's $8.3B InterMune buy continues its buying spree with 'bolt-on' deal, fueling record M&A activity

FDA action plan seeks to close gap in women and minority patient representation in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs